Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Development of therapies directed to specific molecular abnormalities within cancer cells, as exemplified by human epidermal growth factor receptor 2 (HER2), can be a very rewarding strategy in cancer treatment. The integration of genomic and proteomic approaches into the search for therapeutic targets will be more fruitful than either approach alone and allow further individualization of breast cancer therapy.
Substantial progress has been made using aromatase inhibitors in early-stage breast cancer. This article highlights results from recent and ongoing trials of aromatase inhibitors as adjuvant therapy and discusses options for integration of these agents with tamoxifen in various subsets of patients and clinical scenarios.